Literature DB >> 23419287

Progress and pitfalls in Shigella vaccine research.

Eileen M Barry1, Marcela F Pasetti, Marcelo B Sztein, Alessio Fasano, Karen L Kotloff, Myron M Levine.   

Abstract

Renewed awareness of the substantial morbidity and mortality that Shigella infection causes among young children in developing countries, combined with technological innovations in vaccinology, has led to the development of novel vaccine strategies in the past 5 years. Along with advancement of classic vaccines in clinical trials and new sophisticated measurements of immunological responses, much new data has been produced, lending promise to the potential for production of safe and effective Shigella vaccines. Herein, we review the latest progress in Shigella vaccine development within the framework of persistent obstacles.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23419287      PMCID: PMC3747556          DOI: 10.1038/nrgastro.2013.12

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  118 in total

1.  Changing species distribution and antimicrobial susceptibility pattern of Shigella over a 29-year period (1980-2008).

Authors:  F Khatun; A S G Faruque; J L Koeck; P Olliaro; P Millet; N Paris; M A Malek; M A Salam; S Luby
Journal:  Epidemiol Infect       Date:  2010-05-18       Impact factor: 2.451

2.  Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population.

Authors:  D Cohen; M S Green; C Block; T Rouach; I Ofek
Journal:  J Infect Dis       Date:  1988-05       Impact factor: 5.226

3.  Human milk immunoglobulin A antibodies to Shigella virulence determinants.

Authors:  T G Cleary; D K Winsor; D Reich; G Ruiz-Palacios; J J Calva
Journal:  Infect Immun       Date:  1989-06       Impact factor: 3.441

4.  Disease-dependent changes in T-cell populations in patients with shigellosis.

Authors:  D Islam; B Christensson
Journal:  APMIS       Date:  2000-04       Impact factor: 3.205

5.  Structural elucidation of the O-antigen of the Shigella flexneri provisional serotype 88-893: structural and serological similarities with S. flexneri provisional serotype Y394 (1c).

Authors:  R A Foster; N I A Carlin; M Majcher; H Tabor; L-K Ng; G Widmalm
Journal:  Carbohydr Res       Date:  2011-02-15       Impact factor: 2.104

6.  Global burden of Shigella infections: implications for vaccine development and implementation of control strategies.

Authors:  K L Kotloff; J P Winickoff; B Ivanoff; J D Clemens; D L Swerdlow; P J Sansonetti; G K Adak; M M Levine
Journal:  Bull World Health Organ       Date:  1999       Impact factor: 9.408

7.  Safety and immunogenicity of WRSd1, a live attenuated Shigella dysenteriae type 1 vaccine candidate.

Authors:  Robin McKenzie; Malabi M Venkatesan; Marcia K Wolf; Dilara Islam; Shannon Grahek; Andrea M Jones; Arlene Bloom; David N Taylor; Thomas L Hale; A Louis Bourgeois
Journal:  Vaccine       Date:  2008-04-16       Impact factor: 3.641

8.  Safety and immunogenicity of CVD 1208S, a live, oral DeltaguaBA Deltasen Deltaset Shigella flexneri 2a vaccine grown on animal-free media.

Authors:  Karen L Kotloff; Jakub K Simon; Marcela F Pasetti; Marcelo B Sztein; Stacey L Wooden; Sofie Livio; James P Nataro; William C Blackwelder; Eileen M Barry; Wendy Picking; Myron M Levine
Journal:  Hum Vaccin       Date:  2007-07-15

9.  Shigella infection induces cellular activation of T and B cells and distinct species-related changes in peripheral blood lymphocyte subsets during the course of the disease.

Authors:  D Islam; P K Bardhan; A A Lindberg; B Christensson
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

10.  Outer membrane protein A (OmpA) of Shigella flexneri 2a, induces protective immune response in a mouse model.

Authors:  Debasis Pore; Nibedita Mahata; Amit Pal; Manoj K Chakrabarti
Journal:  PLoS One       Date:  2011-07-26       Impact factor: 3.240

View more
  52 in total

1.  Development and preclinical evaluation of a trivalent, formalin-inactivated Shigella whole-cell vaccine.

Authors:  R W Kaminski; M Wu; K R Turbyfill; K Clarkson; B Tai; A L Bourgeois; L L Van De Verg; R I Walker; E V Oaks
Journal:  Clin Vaccine Immunol       Date:  2014-01-08

2.  Characterization of a multicomponent live, attenuated Shigella flexneri vaccine.

Authors:  BreOnna C DeLaine; Tao Wu; Christen L Grassel; Avital Shimanovich; Marcela F Pasetti; Myron M Levine; Eileen M Barry
Journal:  Pathog Dis       Date:  2016-04-21       Impact factor: 3.166

3.  The association between diurnal temperature range and childhood bacillary dysentery.

Authors:  Li-ying Wen; Ke-fu Zhao; Jian Cheng; Xu Wang; Hui-hui Yang; Ke-sheng Li; Zhi-wei Xu; Hong Su
Journal:  Int J Biometeorol       Date:  2015-06-05       Impact factor: 3.787

Review 4.  Salmonella, Shigella, and yersinia.

Authors:  John P Dekker; Karen M Frank
Journal:  Clin Lab Med       Date:  2015-04-02       Impact factor: 1.935

5.  A novel protein-based subunit Shigella vaccine candidate.

Authors:  Malabi M Venkatesan
Journal:  Immunol Cell Biol       Date:  2015-06-09       Impact factor: 5.126

6.  Immunofluorescence Analysis of Stress Granule Formation After Bacterial Challenge of Mammalian Cells.

Authors:  Pascale Vonaesch; Philippe J Sansonetti; Pamela Schnupf
Journal:  J Vis Exp       Date:  2017-07-03       Impact factor: 1.355

7.  Highly homogenous tri-acylated S-LPS acts as a novel clinically applicable vaccine against Shigella flexneri 2a infection.

Authors:  Vladimir A Ledov; Marina E Golovina; Anna A Markina; Yuriy A Knirel; Vyacheslav L L'vov; Alexander L Kovalchuk; Petr G Aparin
Journal:  Vaccine       Date:  2019-01-19       Impact factor: 3.641

Review 8.  The genomic signatures of Shigella evolution, adaptation and geographical spread.

Authors:  Hao Chung The; Duy Pham Thanh; Kathryn E Holt; Nicholas R Thomson; Stephen Baker
Journal:  Nat Rev Microbiol       Date:  2016-02-29       Impact factor: 60.633

9.  An update on vaccines against Shigella.

Authors:  Shai Ashkenazi; Dani Cohen
Journal:  Ther Adv Vaccines       Date:  2013-09

10.  Circulating Gut-Homing (α4β7+) Plasmablast Responses against Shigella Surface Protein Antigens among Hospitalized Patients with Diarrhea.

Authors:  Anuradha Sinha; Ayan Dey; Giulietta Saletti; Pradip Samanta; Partha Sarathi Chakraborty; M K Bhattacharya; Santanu Ghosh; T Ramamurthy; Jae-Ouk Kim; Jae Seung Yang; Dong Wook Kim; Cecil Czerkinsky; Ranjan K Nandy
Journal:  Clin Vaccine Immunol       Date:  2016-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.